

Product datasheet for TL308275

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

ZFYVE27 Human shRNA Plasmid Kit (Locus ID 118813)

Product data:

Product Type: shRNA Plasmids

Product Name: ZFYVE27 Human shRNA Plasmid Kit (Locus ID 118813)

Locus ID: 118813

Synonyms: PROTRUDIN; SPG33

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

Components: ZFYVE27 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID =

118813). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001002261, NM 001002262, NM 001174119, NM 001174120, NM 001174121,

NM 001174122, NM 144588, NM 144588.1, NM 144588.2, NM 144588.3, NM 144588.4, NM 144588.5, NM 144588.6, NM 001002261.1, NM 001002261.3, NM 001002262.1, NM 001002262.2, NM 001002262.3, NM 001174122.1, NM 001174121.1, NM 001174120.1, NM 001174119.1, BC030621, BC030621.2, BM544601, NM 001002262.4, NM 144588.7

UniProt ID: Q5T4F4

Summary: This gene encodes a protein with several transmembrane domains, a Rab11-binding domain


and a lipid-binding FYVE finger domain. The encoded protein appears to promote neurite formation. A mutation in this gene has been reported to be associated with hereditary spastic

paraplegia, however the pathogenicity of the mutation, which may simply represent a

polymorphism, is unclear. [provided by RefSeq, Mar 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).